Effect of Prime Solution on Fluid Balance After Open Heart Surgery
NCT ID: NCT00797589
Last Updated: 2015-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
35 participants
INTERVENTIONAL
2009-01-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect on Fluid Balance After Cardiac Surgery After Use of Two Different Priming Protocols
NCT01511120
Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery
NCT01418521
Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery
NCT03280745
Hypertonic Saline Solution to Prevent Acute Kidney Injury After Heart Transplantation
NCT05909150
Effects of Hypertonic Saline-HES Solution on Extracellular Water in Cardiac Surgery Patients
NCT01348659
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Before admission to the operation theatre, the patients allocate in random order to receive one of the following solutions during the extracorporeal circulation:
1. Ringer-acetate solution
2. 6% HES solution (Tetraspan®) During the 1 postoperative day we register hemodynamic changes, fluid balance, fluid extravasation, plasma ion concentration, modified thromboelastography, and kidney function.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ringer lactate
Crystalloid solution
Ringer lactate
HES solution (Tetraspan®)
Balanced colloid solution
HES
20ml/kg as prime fluid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HES
20ml/kg as prime fluid
Ringer lactate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Kidney failure
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
B. Braun Melsungen AG
INDUSTRY
University of Helsinki
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexey Schramko
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raili T Suojaranta-Ylinen, MD, PhD
Role: STUDY_CHAIR
Helsinki University Central Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helsinki University Central Hospital
Helsinki, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-001225-34
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.